{"id":"W3213113842","doi":"10.1136/ijgc-2021-003017","title":"Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Merck Sharp and Dohme","keywords":"Medicine; Lenvatinib; Pembrolizumab; Internal medicine; Oncology; Endometrial cancer; Carboplatin; Chemotherapy; Cancer; Immunotherapy; Thyroid cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004454522,0.0003207297,0.002129804,0.0002873062,0.0000617503,0.00003402504,0.0004606582,0.0001296847,0.003634058],"category_scores_gemma":[0.002768172,0.0001926131,0.0004670736,0.0005008182,0.0001211401,0.0001581528,0.00009676175,0.0001838334,0.000001169275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001531441,"about_ca_system_score_gemma":0.001047634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000287102,"about_ca_topic_score_gemma":0.0006981269,"domain_scores_codex":[0.9966055,0.0001874139,0.001627623,0.0003726736,0.000927534,0.0002793278],"domain_scores_gemma":[0.9921055,0.003844619,0.001462428,0.0002013709,0.002171058,0.0002150407],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6632645,0.03210618,0.000264795,0.00004475925,0.004342176,0.0001725952,0.0002730714,0.0002162395,0.0005211149,0.00005843296,0.0001607423,0.2985754],"study_design_scores_gemma":[0.9204202,0.05712467,0.000324149,0.0002025389,0.001154178,0.0000308043,0.0002659794,0.0001733098,0.008460093,0.0001242733,0.01154996,0.0001698235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830781,0.006506017,0.000140391,0.002483516,0.004397253,0.002685853,0.0004478339,0.00001039397,0.0002506663],"genre_scores_gemma":[0.9740123,0.02204995,0.00108363,0.0002539702,0.001158566,0.0008157473,0.00005576182,0.00002838813,0.0005416999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2984056,"threshold_uncertainty_score":0.9972768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1565356181272292,"score_gpt":0.4659563725118488,"score_spread":0.3094207543846196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}